PLPC Form 4 — Exercise of 625 Options and Sale at $154.28
Rhea-AI Filing Summary
Morcos Assaad A, Vice President, US Manufacturing of Preformed Line Products Co (PLPC), executed a routine option exercise and sale on 08/04/2025. He exercised the final vested tranche of 625 stock options from a 2022 grant at an exercise price of $61.24 per share and subsequently disposed of 625 common shares at $154.28 per share, leaving 0 direct common shares following the transactions. The filing shows he continues to hold 681 restricted stock units and 7,500 outstanding stock options granted on 12/11/2024 with scheduled vesting through 2027. The form lists the specific vesting schedules for the 2022 and 2024 option grants and confirms the transaction was reported by power of attorney.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine option exercise and immediate sale; not a company-changing event.
The reporting person exercised 625 options at $61.24 and sold the resulting shares at $154.28. This is documented as the final vested tranche from a 2022 grant. The transaction appears procedural: exercise of vested options followed by a sale, leaving the filer with no direct common shares. Material outstanding equity holdings remain in the form of 681 RSUs and 7,500 options from a 2024 grant with multi-year vesting. For investors, this is a disclosure of insider liquidity rather than a change in control or strategic direction.
TL;DR: Disclosure aligns with Rule 16 reporting; transaction details and vesting schedules are clearly stated.
The Form 4 specifies the grant dates, vesting tranches, exercise price, and sale price for the exercised tranche. The explanation clarifies vesting timelines for both the 2022 and 2024 grants and indicates the exercise related to the last vested tranche. The form is signed via power of attorney and reports ownership forms as direct. This is a standard insider reporting event with transparent terms and no governance red flags visible in the filing content.